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INTRODUCTION 
The treatment of macular edema has significantly improved in recent years.1-4 
Intravitreal  triamcinolone acetonide (IVTA) has been shown to improve visual acuity 
(VA) and reduce  central macular thickness (CMT) more effectively than laser treatment 
in different pathologies2,3.   
IVTA is associated with a low incidence of surgical complications but with some well-
known  side effects (increase in intraocular pressure, cataract development).1-4 Several 
aspects of the    off-label use of 4 mg of triamcinolone need to be clarified.  
The recurrence of DMO is related to the disappearance of triamcinolone from the 
vitreous: a mean elimination half-life of 18.6 days has been found and it was estimated 
that 4 mg of triamcinolone would last in the vitreous for 3 months.4 In theory, the half-life 
of this drug should be smaller in previously vitrectomized eyes  due to the lack of the 
vitreous reservoir and a faster wash-out from the vitreous cavity. 
 
PURPOSE 
To analyse the effect of IVTA on CMT in previously vitrectomized eyes.  
 
METHODS      
Retrospective study. 
 
Hospital de Braga, Ophthalmology Department 
 
Eyes with macular edema that had previously underwent 23G pars plana vitrectomy. 
 
The following parameters were analyzed before and after IVTA:: 
•  Best Corrected Visual Acuity (BCVA),  
•  IntraOcular Pressure (IOP), 
•  Mean CMT using Optical Coherence Tomography (Cirrus TM HD-OCT Zeiss 
Meditec®). 
We compared the change in mean CMT and its effect time.  
Statistical analysis were performed using paired-sample t-test. 
 
RESULTS 








































Central Macular Thickness-lowering effect of triamcinolone in vitrectomized eyes lasted 





























Right Eye 6 





Mean (±SD) 11.12 (±4.5) 
Range 2.3 – 14.8 
Cause 




Before IVTA After IVTA paired-sample t-test 
Intraocular Pressure 
(mmHg) 
16.45±2.58 19.85±3.34 0.0041 
Visual Acuity (decimal 
scale) 
0.22±0.17 0.28±0.19 0.1329 
Central Macular 
Thickness 
488.91±144.7 1st IVTA: 
228.64±170,79 
0.0012 
2nd IVTA: 355±121 0.0315 (vs. baseline) 
REFERENCES 
1.  Abraldes MJ, Fernández M, Gómez-Ulla F. Intravitreal Triamcinolone in Diabetic Retinopathy. Current Diabetes Reviews. 2009;5:18-25. 
2.  Spandau U, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas J. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol. 2005;89:999-1003. 
3.  Michael S. Intravitreal Injection of Triamcinolone. Diabetes Care. 2004;27(7). 
4.  Longo A. Intravitreal triamcinolone for diffuse diabetic macular oedema. Br J Ophthalmol. 2006;90:1079-80. 
CONCLUSIONS 
Triamcinolone should be considered in the treatment of patients with persistent macular edema even in vitrectomized eyes. Central Macular Thickness-lowering effect of 
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CMT before and after IVTA per patient 
Before IVTA 
After 1st IVTA 
After 2nd IVTA 
